

**Virginia's Department of Medical Assistance Services**  
**Pharmacy and Therapeutics Committee Meeting**  
*600 East Broad Street – 1<sup>st</sup> Floor Conference Rooms*  
*Richmond, Virginia 23219*  
**Tuesday, July 23, 2024 - 1:00 p.m.**

**Welcome and Comments from DMAS Director**

Cheryl Roberts, JD Medicaid Director  
Lisa Price-Stevens MD, CMO, Chair

**Call to Order**

Lisa Price-Stevens MD, CMO, Chair

**PDL Management**

P&T Committee Members

**Endocrine & Metabolic Agents**

- Weight Management Agents
- Wegovy for Cardiovascular Risk Reduction

**Confidential Meeting (Pricing Information Discussion)**

P&T Committee Members & DMAS Staff

**Criteria Discussion of Weight Management Agents**

P&T Committee Members

**Criteria Discussion of Wegovy for Cardiovascular Risk Reduction**

P&T Committee Members

**Announcements**

DMAS Staff

**Adjournment**

Lisa Price-Stevens MD, CMO, Chair

**Next Meeting - October 2, 2024.**

**Oral Presentations:** The P&T Committee in conjunction with the Department will allocate time slots for interested parties to present scientific and clinical information on PDL Phase I drugs in classes in which are scheduled for review at the September meeting and new PDL Phase II drugs listed on the Agenda. **All presentations must include information published in a peer reviewed journal (per guidelines below) that is clinical in nature and based on scientific material. The references used to authorize presentations must be within the following timeframes:**

- Weight Management Agents Annual Reviews – July 2023 to present
- Wegovy for Cardiovascular Risk Reduction – January 2024 to present

No anecdotal accounts are to be given. Each speaker will be allocated no more than 2 minutes to present. The Chairperson will approve presentation requests based on relevancy of the information.

Anyone interested in providing specific clinical information to the Committee at the meeting must **submit an outline of discussion points, clinical references (within the stated guidelines above) and a written request to speak with the name/title of the presenter.** Please send requested information to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) and [david.damico@primetherapeutics.com](mailto:david.damico@primetherapeutics.com) by 5 p.m. EST on Tuesday July 9th, 2024.

**Written information/comments:** The P&T Committee will also accept written comments for consideration. Please send statements to [pdlinput@dmas.virginia.gov](mailto:pdlinput@dmas.virginia.gov) by 5 p.m. EST on Tuesday July 9th, 2024.

DRAFT